; and (2) except for in vitro clinical tests required to meet the requirements of section 809.30 of title 21, Code of Federal Regulations prior to the effective date of this subchapter specified in section 5(a)(1)(A) of the VALID Act of 2023 , such restrictions described in paragraph (1) shall be deemed to be restrictions under this subchapter as of such effective date. 587P. Appeals (a) Significant decision (1) In general The Secretary shall— (A) maintain a substantive summary of the scientific and regulatory rationale for any significant decision of the Food and Drug Administration pursuant to section 587F, regarding— (i) the submission of an application for, or a review of, an in vitro clinical test under section 587B or section 587D; (ii) an exemption under section 587C; or (iii) any requirements for mitigation measures to an in vitro clinical test or category of in vitro clinical tests